PDE4A and chronic obstructive pulmonary disease: Based on the facts that PDE4 inhibitors suppress inflammatory processes in several cell types involved in COPD [59], inhibit cellular trafficking and microvascular leakage, produce reactive oxygen species, express cell adhesion molecules [60] and mediate lung smooth muscle relaxation, selective inhibitors have been developed for the treatment of COPD [61].